A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 302 participants.
Also called NCT01043029
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 302 participants
- Sponsor
- Registry
-
NCT01043029
-
- Other papers using this trial's data
- Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Australia, Brazil, Colombia, El Salvador, Germany, Hong Kong SAR China, Hungary, Italy, Mexico, Peru, Romania, Russia, Slovakia
- Registry status
- Completed
Technical summary
Registry record NCT01043029. Randomized; double masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2012-07 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment
- Condition
- Diabetes Mellitus Type 2
- Intervention (Drug)
- aleglitazar
- Intervention (Drug)
- pioglitazone
- Lead sponsor
- Hoffmann-La Roche
Record details
- Record id
cardio:ct-nct01043029- Content hash
449b5c436be46a9c6d4763322cb7dd2a04e74832bdff15abe2c1d0fe2ae49dbc